Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subse... Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 11.96 | 11.96 | 11.96 | 4210 | 11.96 | DE |
| 26 | 0 | 0 | 11.96 | 11.96 | 11.96 | 2391 | 11.96 | DE |
| 52 | 0 | 0 | 11.96 | 11.96 | 11.96 | 3043 | 11.96 | DE |
| 156 | 0 | 0 | 11.96 | 11.96 | 11.96 | 84504 | 11.96 | DE |
| 260 | 0 | 0 | 11.96 | 11.96 | 11.96 | 49554 | 11.96 | DE |
price_and_volume
5分前
LTListener
5分前
Mozy429
7分前
Coo breeze
7分前
otcstardmn
7分前
HenryB3
7分前
mikeo56
7分前
LOB
8分前
chill-will 1
8分前
WhatMoney?
8分前
chen1992
9分前
Wallstreeter$$$
9分前
meixatech
9分前
otcstardmn
9分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。